Gilead(US:GILD) ZACKSยท2025-10-03 23:00Core Insights - Gilead Sciences (GILD) stock closed at $112.69, reflecting a +1.93% change from the previous day, outperforming the S&P 500's gain of 0.01% [1] - The stock has decreased by 1.96% over the past month, underperforming the Medical sector's increase of 4.67% and the S&P 500's rise of 4.83% [1] Earnings Performance - Gilead Sciences is expected to report an EPS of $2.15, representing a 6.44% increase from the same quarter last year [2] - Revenue is forecasted at $7.43 billion, indicating a 1.59% decline compared to the same quarter last year [2] Annual Estimates - For the annual period, earnings are anticipated to be $8.08 per share, with revenue projected at $28.75 billion, reflecting increases of +74.89% and no change, respectively, from the previous year [3] Analyst Sentiment - Recent changes in analyst estimates suggest optimism regarding Gilead Sciences' business and profitability [3] - The Zacks Consensus EPS estimate has decreased by 0.21% over the last 30 days, and Gilead Sciences currently holds a Zacks Rank of 3 (Hold) [5] Valuation Metrics - Gilead Sciences has a Forward P/E ratio of 13.68, which is lower than the industry average of 19.42, indicating it is trading at a discount [6] - The PEG ratio for Gilead Sciences is currently 0.75, compared to the industry average of 1.82, suggesting favorable valuation relative to growth expectations [7] Industry Context - The Medical - Biomedical and Genetics industry, where Gilead operates, has a Zacks Industry Rank of 74, placing it in the top 30% of over 250 industries [7] - Research indicates that top-rated industries outperform lower-rated ones by a factor of 2 to 1 [8]